Navigation Links
FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
Date:1/7/2011

SILVER SPRING, Md., Jan. 7, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Abstral (fentanyl) transmucosal tablets to manage breakthrough pain for adults with cancer.  Fentanyl immediate-release transmucosal medications are administered on the soft surfaces of the mouth (inside of the cheek, gums, tongue), or the nasal passages or throat where they dissolve and are absorbed.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

"This is an important step for patients with cancer pain to have options for the treatment of their breakthrough pain," said John Jenkins, M.D., director of FDA's Office of New Drugs in the Center for Drug Evaluation and Research.

Abstral is indicated for the management of breakthrough pain in patients with cancer, ages 18 years and older, who already use opioid pain medication around the clock and who need and are able to safely use high doses of an additional opioid medicine.  Breakthrough pain is pain that comes on suddenly for short periods of time and is not alleviated by a patient's normal pain management plan. These patients are considered opioid tolerant because of their current opioid medication use.  Only health care professionals skilled in the use of Schedule II opioids to treat pain should prescribe this drug product.  

Abstral is available only through a Risk Evaluation and Mitigation Strategy (REMS) program, which is intended to minimize the risk of misuse, abuse, addiction and overdose.  Under this program, pharmacies, distributors, and health care professionals who prescribe to outpatients are required to enroll in the program to prescribe, dispense and distribute this product.  FDA has standardized key components of the REMS program to facilitate the adoption of a single shared system. These components include the REMS document, the Patient-Prescriber Agreement, and the enrollment form. These components can be used by all sponsors of immediate release transmucosal fentanyl products to develop individual REMS programs  such as the program approved for Abstral.  FDA has also directed the sponsors of this class of products to work together on a single shared system to implement the REMS.  

"This approval is also a significant step toward reducing the burden on the health care system of implementing REMS programs," added Dr. Jenkins. "When fully implemented, FDA expects that prescribers, pharmacies, and distributors of all immediate release transmucosal fentanyl products will be able to use standardized materials and a single shared system to implement the REMS."

The safety of Abstral was evaluated in 311 opioid-tolerant cancer patients with breakthrough pain.  Two hundred and seventy of these patients were treated in multiple-dose studies. The duration of therapy for patients in multiple-dose studies ranged from 1-405 days with an average duration of 131 days and with 44 patients treated for at least 12 months.

Common adverse reactions include nausea, constipation, drowsiness and headache. Serious adverse events, including deaths, have been reported in patients with other immediate-release transmucosal fentanyl products. The deaths occurred as a result of improper patient selection and/or improper dosing.  

Consumers and health care professionals are encouraged to report adverse side effects or medication errors from the use of Abstral to the FDA's MedWatch Adverse Event Reporting program at http://www.fda.gov/MedWatch or by calling 800-332-1088.

Abstral is manufactured by ProStraken Inc., based in Bedminister, N.J.

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
2. FDA Approves New Dosage Strength for INTELENCE®
3. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
4. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
5. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
6. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
7. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
8. FDA Approves New Treatment Option for Late-Stage Breast Cancer
9. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
10. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
11. FDA Approves New Indication for Afinitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/12/2017)... and Canada joint tech company Laughing Face has ... detergent, and features a powerful disinfection process. The company ... washes and sanitizes women,s panties or babies, cloth diapers in 25 ... ... an external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 19, 2017 , ... HealthSmart, the largest independent ... (Jim) Vertino as Chief Information Officer (CIO). He will be joining HealthSmart at ... and business performance. He defines strategic roadmaps by reimagining business processes—bridging the gap ...
(Date:5/21/2017)... ... 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. No matter what people ... attributes like never before. More than a map, new social marketplace Weedable ... products – and for the first time – each other. A social marketplace like ...
(Date:5/21/2017)... ... May 21, 2017 , ... For more than 20 ... a wide range of knives and swords, from functional to fantasy. United Cutlery has ... with sleek, modern designs that defy tradition. , Offering a range of weapons and ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... In a ... PlushBeds , a luxury online mattress company that specializes in natural and organic ... nation’s leading grassroots autism organization) for every unique share their recent viral Facebook ...
(Date:5/19/2017)... Mo (PRWEB) , ... May 19, 2017 , ... When ... May 20, his name will already appear on two major research studies that could ... been working with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an ...
Breaking Medicine News(10 mins):